… The aim of this analysis was to report the safety and efficacy of erlotinib in the Australian … ,
recruitment continued until erlotinib was licensed. Results from the global TRUST study and a …

… In the present study, we further confirmed the efficacy and safety profile of erlotinib in Chinese
NSCLC patients who did not respond to previous chemotherapy, especially in the patients …

… from erlotinib … TRUST study provided access to erlotinib for suitable patients in countries
prior to licensing, and provided an opportunity to assess the efficacy and safety of erlotinib in a …

… efficacy and tolerability of erlotinib as second-line therapy in a broad patient population. The
TRUST study … As such, conclusions regarding efficacy are tempered by the limitations of any …

Erlotinib has been shown to prolong progression‐free ( PFS ) and overall survival ( OS ) in
patients with advanced non‐small cell lung cancer ( NSCLC ). We report here on …

… The outcomes with erlotinib in this study are generally consistent with those from the phase
III erlotinib study. The response rates were similar (7.9 and 8.9%, respectively), but here the …

… patients in this study received erlotinib as a fourth-line or subsequent treatment, the results
from this study were similar to those of clinical studies. We deduce that erlotinib is effective …

… The findings of the study confirmed the favourable efficacy and safety profile of erlotinib in a
… and well tolerated as a first-line treatment for elderly patients involved in the TRUST study. …

… Here, we report final data from the global population of the TRUST study. … benefit from
erlotinib therapy. There were no unexpected safety findings relating to erlotinib in this study. As the …

… Of the 1345 Asian patients enrolled in the TRUST study, we report data from the subpopulation
of patients who were recruited in E/SE Asia (n = 1242), including those from the following …